Elevation Oncology to Participate at the JMP Securities Hematology and Oncology Summit

On November 30, 2022 Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, reported that Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 6, 2022 at 11:00 am ET (Press release, Elevation Oncology, NOV 30, 2022, View Source;utm_medium=rss&utm_campaign=elevation-oncology-to-participate-at-the-jmp-securities-hematology-and-oncology-summit [SID1234624598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and replay of this event will be available on the Events page of the Company’s Investor Relations website at View Source